Ken Griffin Iovance Biotherapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$7.28 - $11.9 $1.7 Million - $2.77 Million	232,900 Added 54.96%	656,700 $6.17 Million
Q2 2024 Aug 14, 2024	BUY	$7.78 - $14.19 $371,884 - $678,282	47,800 Added 12.71%	423,800 $3.4 Million
Q1 2024 May 15, 2024	SELL	$7.59 - $17.47 $86,526 - $199,158	-11,400 Reduced 2.94%	376,000 $5.57 Million
Q4 2023 Feb 14, 2024	SELL	$3.3 - $8.89 $484,770 - $1.31 Million	-146,900 Reduced 27.49%	387,400 $3.15 Million
Q3 2023 Nov 14, 2023	BUY	$4.44 - $8.79 $1.57 Million - $3.11 Million	353,700 Added 195.85%	534,300 $2.43 Million
Q2 2023 Aug 14, 2023	BUY	$5.36 - $9.06 $369,840 - $625,140	69,000 Added 61.83%	180,600 $1.27 Million
Q1 2023 May 15, 2023	SELL	$5.53 - $8.22 $106,176 - $157,824	-19,200 Reduced 14.68%	111,600 $681,000
Q4 2022 Feb 14, 2023	BUY	$5.62 - $10.0 $336,076 - $598,000	59,800 Added 84.23%	130,800 $835,000
Q3 2022 Nov 14, 2022	SELL	$9.53 - $13.11 $300,195 - $412,965	-31,500 Reduced 30.73%	71,000 $680,000

313

237M

3.77M

1.7M

Ticker IOVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 157,800,992
Market Cap $1.18B
Description
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.